| Website | curevac.com |
| Category | BioTech |
| Phone | 49(0)-70-71-9-20-53-0 |
| Employees |
| TOTAL | $67M |
| VENTURE FUNDING TOTAL | $67M |
| Series B, 1/06 DH Capital OH Beteiligungen | €22M |
| Series C, 5/10 dievini Hopp Biotech Holding | $34.9M |
CureVac GmbH is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA (mRNA). CureVac's lead programme is dedicated to the development of active immunotherapies (based on its RNActive® technology) for the treatment of prostate cancer and non-small cell lung cancer. Furthermore, in preclinical studies, CureVac is developing prophylactic vaccines and adjuvants to address infectious diseases.
